论文信息 - The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia - 字舞流文

The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia

Martin C. Müller | D. Niederwieser | M. Cross | A. Hochhaus | T. Ernst | T. Lange | F. Gruber | M. Pfirrmann | J. Maier